PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Teams with UniQuest to Develop Novel Cannabinoid Delivery System

  • Global nasal drug delivery technology market expected to reach $64 billion by 2021
  • Development of CBD-infused soluble gel for nasal delivery targets range of diseases
  • Clinical benefits of Sol-gel delivery method include a safer, more reliable delivery platform with higher efficacy

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and UniQuest Pty Limited, the main commercialization company of the University of Queensland (UQ), Australia, are expecting 2018 to be an exciting, productive year for joint medical research projects. PreveCeutical Medical, headquartered in Vancouver, British Columbia, has entered into a research and option agreement with the University and UniQuest to develop a soluble gel to deliver cannabinoids directly to the brain via the nasal cavity. In a press release discussing the latest research project, UniQuest CEO Dr. Dean Moss said that PreveCeutical’s interest in the University’s intellectual property and expertise to develop soluble gels (Sol-gels) to deliver cannabinoids to the central nervous system (CNS) fit naturally with the company’s research goals (http://cnw.fm/zIB24).

“Sol-gels potentially provide a safer, more reliable platform to deliver drugs, such as cannabinoids, directly to the CNS, avoiding unwanted rapid metabolism, thus providing clinical benefit from direct nose-to-brain delivery,” Dr. Moss said in the release.

The global nasal drug delivery technology market is projected to reach $64 billion by 2021, expanding at a compound annual growth rate of 6.5 percent, according to a report issued by MarketsandMarkets (http://cnw.fm/x9T1Q). While the report is segmented based on dosage form, therapeutic application, end user, system, container and region, it also states “intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.”

PreveCeutical’s proprietary nasal formulations will be designed as a CBD-based nose-to-brain delivery system targeting a range of indications such as pain, inflammation, seizures and neurological disorders. Dr. Harry Parekh, chief research officer for PreveCeutical, will lead the Sol-gel cannabinoid project from his base at the University’s School of Pharmacy.

The Sol-gels begin as a liquid that is sprayed into the nose, which then forms a gel as it is warmed in the nasal cavity. This effectively bypasses the stomach and intestines – eliminating first pass metabolism – and may dramatically improve bioavailability, even compared to nasal sprays and other newer delivery systems.

“This feature can potentially be exploited to deliver drugs through the nasal mucosa,” Dr. Parekh said. “The longer-term goal is to develop Sol-gels as safe, reliable delivery systems for cannabinoid extracts across a range of disease indications.”

Terms of the research program, which has a target start date of March 1, 2018, state that PreveCeutical will own all intellectual property developed under the program and will be granted an option to negotiate an exclusive worldwide license to UniQuest’s background IP.

“Increasing evidence of the clinical benefits associated with cannabinoids and the recent legalization of medical marijuana across a number of jurisdictions were the drivers for the collaboration,” Stephen Van Deventer, PreveCeutical chairman and CEO, added in a news release. “Working with UniQuest and UQ will provide the company with unique opportunities to develop new health and wellness products… Nasal delivery of cannabinoids could potentially provide a safer and more reliable delivery platform with clinical benefits for pain, inflammation, seizures, and mental illness.”

For more information, visit the company’s website at www.PreveCeutical.com

More from CannabisNewsWire

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net

Archives

Select A Month

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722